CNST - MorphoSys at a historic low as it completes acquisition of Constellation Pharma

Zhanna Hapanovich/iStock via Getty Images MorphoSys AG (MOR) announced the completion of the previously-announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals (CNST) which is in a deal to be acquired by the company for $1.7B. The transaction was financed by an upfront payment of $1.4B received as part of a long-term strategic funding partnership with Royalty Pharma. The tender offer of $34.00 per share expired on July 14, 2021, the company said.  Constellation shares will no longer trade on The NASDAQ Global Select Market after the merger which is set to close today before the start of trading. Additional details on the operations of the combined company are expected on July 29 when MorphoSys releases Q2 2021 earnings. As indicated in the graph, the company shares have reached an all-time low.

For further details see:

MorphoSys at a historic low as it completes acquisition of Constellation Pharma